

Endoscopic Retrograde Cholangiopancreatography/ERCP Market by Product (Upper GI endoscopes, Stent, Balloons, Catheters, Baskets), Procedure (Biliary Sphincterotomy & Stenting, Pancreatic Sphincterotomy), End User (Hospitals) - Global Forecast to 2026

<https://marketpublishers.com/r/ECA7122C8DF9EN.html>

Date: March 2022

Pages: 231

Price: US\$ 4,950.00 (Single User License)

ID: ECA7122C8DF9EN

Abstracts

The global endoscopic retrograde cholangiopancreatography market is projected to reach USD 2.0 billion by 2026 from USD 1.3 billion in 2021, at a CAGR of 9.6% during the forecast period. The growth of this market is majorly attributed to factors such as the rising incidence of cancer, increasing investments by governments and healthcare organizations to improve endoscopy research, growing focus on investments by hospitals for advanced endoscopy instruments, and the increasing preference for minimally invasive surgeries. On the other hand, the high costs of endoscopic retrograde cholangiopancreatography devices, the development of other procedures like EUS and MRCP, and the shortage of trained physicians and endoscopists are factors expected to restrain the market growth to a certain extent.

“The endotherapy devices segment accounted for the largest share of the endoscopic retrograde cholangiopancreatography market in 2020.”

Based on products, the endoscopic retrograde cholangiopancreatography market has been segmented into endoscopes, endotherapy devices, visualization systems, energy devices, and others. The factors attributing to the large revenue of the endotherapy devices segment include the growing preference for minimally invasive surgeries and the increasing prevalence of gastrointestinal conditions.

“The markets in Asia Pacific and Latin America is projected to witness the highest growth rate during the forecast period (2021–2026).”

North America accounted for the largest share of the Endoscopic retrograde cholangiopancreatography market in 2020. The increasing prevalence of cancer, high investments by hospitals to purchase new ERCP equipment, and a strong focus on research activities to improve endoscopy techniques are the major factor contributing to this.

A breakdown of the primary participants referred to for this report is provided below:

By Company Type (Supply-side): Tier 1: 55%, Tier 2: 25%, and Tier 3: 20%

By Designation: C-level: 43%, Director-level: 32%, and Others: 25%

By Region: North America: 38%, Europe: 23%, Asia-Pacific: 29%, Latin America: 5%, and Middle East & Africa: 5%

The major players in the global endoscopic retrograde cholangiopancreatography market include Olympus Corporation (Japan), CONMED Corporation (US), Fujifilm Holdings Corporation (Japan), HOYA Corporation (Japan), KARL STORZ SE & Co. KG (Germany), Ambu A/S (Denmark), Boston Scientific Corporation (US), Johnson & Johnson (US), Medtronic, PLC (Ireland), Cook Medical (US), and B. Braun Melsungen AG (Germany).

Other players in the market include Hobbs Medical, Inc. (US), STERIS PLC (US), Merit Medical Systems, Inc. (US), TeleMed Systems, Inc. (US), Changzhou Health Microport Medical Device Co., LTD. (China), Medi-Globe GmbH (Germany), Taewoong Medical Co., Ltd. (South Korea), Huger Medical Instrument Co., Ltd. (China), IntroMedic Co., Ltd. (Republic of Korea), SonoScape Medical Corporation (China), Shanghai AOHUA Photoelectricity Endoscope Co., Ltd. (China), Ottomed (India), Kimberly-Clark Corporation (US), and Shaili Endoscopy (India).

Research Coverage:

The report analyzes the endoscopic retrograde cholangiopancreatography market and aims at estimating the market size and future growth potential of this market based on various segments such as product, and region. The report also includes competitive

analysis of the key players in this market along with their company profiles, product offerings, recent developments, and key market strategies.

Reasons to Buy the Report

The report can help established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them garner a greater share. Firms purchasing the report could use one, or a combination of the below mentioned five strategies.

This report provides insights into the following pointers:

Market Penetration: Comprehensive information on the product portfolios of the top players in the endoscopic retrograde cholangiopancreatography market. The report analyzes the market based on the products and region.

Product Development/Innovation: Detailed insights on upcoming technologies, research and development activities, and product launches in the endoscopic retrograde cholangiopancreatography market.

Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various types of endoscopic retrograde cholangiopancreatography solutions across regions.

Market Diversification: Exhaustive information about products, untapped regions, recent developments, and investments in the endoscopic retrograde cholangiopancreatography market.

Competitive Assessment: In-depth assessment of market shares, strategies, products, distribution networks, and manufacturing capabilities of the leading players in the endoscopic retrograde cholangiopancreatography markets.

Contents

1 INTRODUCTION

1.1 STUDY OBJECTIVES

1.2 MARKET DEFINITION

1.2.1 INCLUSIONS AND EXCLUSIONS

1.3 MARKET SCOPE

1.3.1 MARKETS COVERED

FIGURE 1 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET

1.3.2 YEARS CONSIDERED

1.4 CURRENCY

1.5 LIMITATIONS

1.6 STAKEHOLDERS

2 RESEARCH METHODOLOGY

2.1 RESEARCH DATA

FIGURE 2 RESEARCH DESIGN

2.1.1 SECONDARY DATA

2.1.1.1 Key data from secondary sources

2.1.2 PRIMARY DATA

FIGURE 3 PRIMARY SOURCES

2.1.2.1 Key data from primary sources

2.1.2.2 Key industry insights

FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS (ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET)

FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS (SUPPLY SIDE): BY COMPANY TYPE, DESIGNATION, AND REGION

2.2 MARKET SIZE ESTIMATION

FIGURE 6 SUPPLY-SIDE MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS

FIGURE 7 REVENUE SHARE ANALYSIS ILLUSTRATION: OLYMPUS CORPORATION

FIGURE 8 SUPPLY-SIDE MARKET SIZE ESTIMATION: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET (2020)

FIGURE 9 CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS,

OPPORTUNITIES, AND CHALLENGES FOR THE ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET (2021–2026)

FIGURE 10 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS

FIGURE 11 TOP-DOWN APPROACH

2.3 MARKET BREAKDOWN AND DATA TRIANGULATION

FIGURE 12 DATA TRIANGULATION METHODOLOGY

2.4 MARKET SHARE ESTIMATION

2.5 STUDY ASSUMPTIONS

2.6 LIMITATIONS

2.6.1 METHODOLOGY-RELATED LIMITATIONS

2.7 RISK ASSESSMENT

2.8 ASSESSMENT OF IMPACT OF COVID-19 ON ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET

3 EXECUTIVE SUMMARY

FIGURE 13 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PRODUCT, 2021 VS. 2026 (USD MILLION)

FIGURE 14 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PROCEDURE, 2021 VS. 2026 (USD MILLION)

FIGURE 15 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY END USER, 2021 VS. 2026 (USD MILLION)

FIGURE 16 GEOGRAPHICAL SNAPSHOT OF THE ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET

4 PREMIUM INSIGHTS

4.1 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET OVERVIEW

FIGURE 17 INCREASING INCIDENCE OF CANCER AND THE GROWING PREFERENCE FOR MINIMALLY INVASIVE SURGERIES ARE THE KEY FACTORS DRIVING MARKET GROWTH

4.2 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET: GEOGRAPHICAL GROWTH OPPORTUNITIES

FIGURE 18 CHINA TO WITNESS THE HIGHEST GROWTH IN THE ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET DURING THE FORECAST PERIOD

4.3 NORTH AMERICA: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PRODUCT AND COUNTRY (2020)

FIGURE 19 THE ENDOSCOPES SEGMENT ACCOUNTED FOR THE LARGEST SHARE OF THE ERCP MARKET IN NORTH AMERICA FOR 2020

4.4 REGIONAL MIX: ENDOSCOPIC RETROGRADE

CHOLANGIOPANCREATOGRAPHY MARKET (2021–2026)

FIGURE 20 THE ASIA PACIFIC AND LATIN AMERICA REGIONS ARE EXPECTED TO REGISTER THE HIGHEST GROWTH RATE DURING THE FORECAST PERIOD (2021–2026)

4.5 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET: DEVELOPED VS. DEVELOPING MARKETS

FIGURE 21 DEVELOPING MARKETS TO REGISTER HIGHER GROWTH DURING THE FORECAST PERIOD

5 MARKET OVERVIEW

5.1 INTRODUCTION

5.2 MARKET DYNAMICS

FIGURE 22 MARKET DYNAMICS: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET

5.2.1 MARKET DRIVERS

5.2.1.1 Rising incidence of cancer

FIGURE 23 GLOBAL AGE-STANDARDIZED INCIDENCE RATES OF PANCREATIC CANCER, 2020

5.2.1.2 Increasing investments, funds, and grants by governments and healthcare organizations to improve endoscopy research

TABLE 1 MAJOR DEVELOPMENTS

5.2.1.3 Growing focus on investments by hospitals for advanced endoscopy instruments

TABLE 2 SOME EXAMPLES OF INVESTMENTS BY HOSPITALS FOR ENDOSCOPY INSTRUMENTS

5.2.1.4 Increasing preference for minimally invasive surgeries

FIGURE 24 ENDOSCOPIC GLOBAL MINIMALLY INVASIVE MARKET SIZE (2019-2030)

5.2.2 MARKET RESTRAINTS

5.2.2.1 High costs of endoscopic retrograde cholangiopancreatography devices

5.2.2.2 Development of other procedures like EUS and MRCP

5.2.2.3 Shortage of trained physicians and endoscopists

5.2.3 MARKET OPPORTUNITIES

5.2.3.1 The growing healthcare sector in emerging economies

5.2.3.2 Increasing adoption of single-use endoscopy instruments

5.2.4 MARKET CHALLENGES

5.2.4.1 Product recalls witnessed by major market players

TABLE 3 LIST OF PRODUCT RECALLS

5.2.4.2 Side-effects and infections (like post-ERCP pancreatitis) caused by duodenoscopy products

6 INDUSTRY INSIGHTS

6.1 INTRODUCTION

6.2 TECHNOLOGY TRENDS

6.2.1 ARTIFICIAL INTELLIGENCE IN GI ENDOSCOPY

TABLE 4 AI SYSTEMS AND OTHER RELATED FUNCTIONS

6.2.2 SINGLE-USE ENDOSCOPES

TABLE 5 ADVANTAGES OF DISPOSABLE OR SINGLE-USE ENDOSCOPES OVER REUSABLE ENDOSCOPES

6.2.3 ROBOT-ASSISTED ENDOSCOPES

TABLE 6 ROBOT-ASSISTED ENDOSCOPY PRODUCTS

6.3 INDUSTRY TRENDS

6.3.1 FAVOURABLE REIMBURSEMENT SCENARIO FOR SINGLE-USE DEVICES

6.4 PRICING ANALYSIS

TABLE 7 AVERAGE SELLING PRICE OF FLEXIBLE HD AND NON-HD DUODENOSCOPE (USD)

TABLE 8 US: AVERAGE COST OF ERCP PROCEDURES, 2020 (USD)

6.5 VALUE CHAIN ANALYSIS

FIGURE 25 VALUE CHAIN ANALYSIS: MAXIMUM VALUE IS ADDED DURING THE MANUFACTURING PHASE

6.6 ECOSYSTEM MAPPING

FIGURE 26 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET: ECOSYSTEM ANALYSIS

6.7 SUPPLY CHAIN ANALYSIS

FIGURE 27 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET: STAKEHOLDERS IN SUPPLY CHAIN

6.8 PORTER'S FIVE FORCES ANALYSIS

TABLE 9 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET: PORTER'S FIVE FORCES ANALYSIS

6.8.1 THREAT OF NEW ENTRANTS

6.8.1.1 High capital requirement

6.8.1.2 High preference for products from well-established brands

6.8.2 THREAT OF SUBSTITUTES

6.8.2.1 Substitute therapies for ERCP procedures

6.8.3 BARGAINING POWER OF SUPPLIERS

6.8.3.1 Presence of several raw material suppliers

6.8.3.2 Supplier switching costs

6.8.4 BARGAINING POWER OF BUYERS

6.8.4.1 Few companies offer premium products at the global level

6.8.5 INTENSITY OF COMPETITIVE RIVALRY

6.8.5.1 Increasing demand for high-quality and innovative products

6.8.5.2 Lucrative growth potential in emerging markets

6.9 REGULATORY ANALYSIS

6.10 PATENT ANALYSIS

6.10.1 PATENT PUBLICATION TRENDS FOR ERCP

FIGURE 28 GLOBAL PATENT PUBLICATION TRENDS IN ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, 2017–2021

6.10.2 TOP APPLICANTS (COMPANIES) OF ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY PATENTS

FIGURE 29 TOP COMPANIES THAT APPLIED FOR ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY PATENTS, 2017–2021

6.10.3 JURISDICTION ANALYSIS: TOP APPLICANTS (COUNTRIES) FOR PATENTS IN ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET

FIGURE 30 JURISDICTION ANALYSIS: TOP APPLICANT COUNTRIES FOR ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY PATENTS, 2017–2021

6.11 TRADE ANALYSIS

TABLE 10 NUMBER OF EXPORTS AND IMPORTS RELATED TO ERCP EQUIPMENT

6.12 IMPACT OF COVID-19 ON THE ENDOSCOPY EQUIPMENT MARKET

7 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PRODUCT

7.1 INTRODUCTION

TABLE 11 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)

7.2 ENDOSCOPES

7.2.1 THE RISING PREFERENCE FOR MINIMALLY INVASIVE SURGERIES IS EXPECTED TO DRIVE THE ENDOSCOPES MARKET

TABLE 12 ENDOSCOPES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)

7.3 ENDOTHERAPY DEVICES

7.3.1 THESE ARE MINIMALLY INVASIVE DEVICES USED TO TREAT OR DIAGNOSE GI CONDITIONS

TABLE 13 ENDOTHERAPY DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)

TABLE 14 ENDOTHERAPY DEVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)

7.3.2 SPHINCTEROTOME

7.3.2.1 The risk of bleeding post-sphincterotomy is 2%, with 0.1% mortality

TABLE 15 SPHINCTEROTOME MARKET, BY COUNTRY, 2019–2026 (USD MILLION)

7.3.3 LITHOTRIPTER

7.3.3.1 Lithotripters are used to pulverize stones into smaller pieces so that they can pass out of a body naturally

TABLE 16 LITHOTRIPTER MARKET, BY COUNTRY, 2019–2026 (USD MILLION)

7.3.4 STENTS

7.3.4.1 Metal stents have higher patency rates and are less expensive than plastic stents

TABLE 17 STENTS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)

7.3.5 CANNULAS

7.3.5.1 The success rate of ERCP procedures is directly proportional to cannulation

TABLE 18 CANNULAS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)

7.3.6 FORCEPS

7.3.6.1 The prevalence of cancer leads to significant demand for biopsy forceps for the collection of tissue samples

TABLE 19 FORCEPS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)

7.3.7 SNARES

7.3.7.1 Snares are commonly used for cold or hot polypectomy

TABLE 20 SNARES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)

7.3.8 CATHETERS

7.3.8.1 Catheters inject a contrast medium for the visualization of internal tissues

TABLE 21 CATHETERS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)

7.3.9 GUIDING WIRES

7.3.9.1 The most used guidewires in ERCP come in three different diameters: 0.018, 0.025, and 0.035 inches

TABLE 22 GUIDING WIRES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)

7.3.10 BALLOONS

7.3.10.1 Balloon endoscopy involves balloons that inflate and deflate to pinch together the walls of the GI tract

TABLE 23 BALLOONS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)

7.3.11 BASKETS

7.3.11.1 Baskets are commonly used instruments for the removal of bile duct stones in ERCP

TABLE 24 BASKETS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)

7.4 VISUALIZATION SYSTEMS

7.4.1 VISUALIZATIONS SYSTEMS HAVE APPLICATIONS ACROSS ALL ERCP PROCEDURES

TABLE 25 VISUALIZATION SYSTEMS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)

7.5 ENERGY DEVICES

7.5.1 ENERGY DEVICES CAN BE MONOPOLAR OR BIPOLAR

TABLE 26 ENERGY DEVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)

7.6 OTHERS

TABLE 27 ERCP ACCESSORIES AND DESCRIPTIONS

TABLE 28 OTHERS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)

8 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PROCEDURE

8.1 INTRODUCTION

TABLE 29 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PROCEDURE, 2019–2026 (USD MILLION)

8.2 BILIARY SPHINCTEROTOMY

8.2.1 INCREASING INCIDENCE RATES OF SOD TO DRIVE THE GROWTH OF THIS SEGMENT

TABLE 30 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET FOR BILIARY SPHINCTEROTOMY, BY COUNTRY, 2019–2026 (USD MILLION)

8.3 BILIARY DILATATION

8.3.1 HIGH-CHOLESTEROL DIETS AND OBESITY ARE THE KEY CAUSES OF GALLSTONES, THUS DRIVING THE UPTAKE OF BILIARY DILATATION PROCEDURES

TABLE 31 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET FOR BILIARY DILATATION, BY COUNTRY, 2019–2026 (USD MILLION)

8.4 BILIARY STENTING

8.4.1 THE RISING PREVALENCE OF GALLBLADDER DISEASES IN THE GROWING GERIATRIC POPULATION IS EXPECTED TO PROPEL THE DEMAND FOR BILIARY STENTS

TABLE 32 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET FOR BILIARY STENTING, BY COUNTRY, 2019–2026 (USD MILLION)

8.5 PANCREATIC SPHINCTEROTOMY

8.5.1 THE RISING INCIDENCE OF PANCREATIC CANCER IS EXPECTED TO DRIVE THE DEMAND FOR THIS PROCEDURE

TABLE 33 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET FOR PANCREATIC SPHINCTEROTOMY, BY COUNTRY, 2019–2026 (USD MILLION)

8.6 PANCREATIC DUCT DILATATION

8.6.1 BALLOON DILATION ALONG WITH ENDOSCOPIC SPHINCTEROTOMY IS THE PREFERRED PROCEDURE FOR STONE REMOVAL

TABLE 34 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET FOR PANCREATIC DUCT DILATATION, BY COUNTRY, 2019–2026 (USD MILLION)

8.7 PANCREATIC DUCT STENTING

8.7.1 PANCREATIC DUCT STENTING IS THE TREATMENT OF CHOICE FOR CHRONIC PANCREATIC DISORDERS

TABLE 35 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET FOR PANCREATIC DUCT STENTING, BY COUNTRY, 2019–2026 (USD MILLION)

9 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY END USER

9.1 INTRODUCTION

TABLE 36 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY END USER, 2019–2026 (USD MILLION)

9.2 HOSPITALS

9.2.1 INCREASING INVESTMENTS BY GOVERNMENT ORGANISATIONS BOOST THE ADOPTION OF ERCP BY THIS END-USER SEGMENT

TABLE 37 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET FOR HOSPITALS, BY COUNTRY, 2019–2026 (USD MILLION)

9.3 AMBULATORY SURGERY CENTERS/CLINICS

9.3.1 AMBULATORY SURGERY CENTERS PROVIDE OUTPATIENT ERCP PROCEDURES THROUGH EFFICIENT OPERATIONS

TABLE 38 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET FOR AMBULATORY SURGERY CENTERS/CLINICS, BY COUNTRY, 2019–2026 (USD MILLION)

9.4 OTHER END USERS

TABLE 39 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET FOR OTHER END USERS, BY COUNTRY, 2019–2026 (USD MILLION)

10 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY REGION

10.1 INTRODUCTION

FIGURE 31 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

TABLE 40 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY REGION, 2019–2026 (USD MILLION)

10.2 NORTH AMERICA

FIGURE 32 NORTH AMERICA: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SNAPSHOT

TABLE 41 NORTH AMERICA: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY COUNTRY, 2019–2026 (USD MILLION)

TABLE 42 NORTH AMERICA: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)

TABLE 43 NORTH AMERICA: ENDOTHERAPY DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)

TABLE 44 NORTH AMERICA: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PROCEDURE, 2019–2026 (USD MILLION)

TABLE 45 NORTH AMERICA: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY END USER, 2019–2026 (USD MILLION)

10.2.1 US

10.2.1.1 The large market in the US is mainly driven by high healthcare spending in the country and the increasing incidence of cancer

TABLE 46 MEDICARE NATIONAL AVERAGE COVERAGE FOR OUTPATIENT PROCEDURES, 2020

TABLE 47 LIST OF DEVICES THAT RECEIVED FDA APPROVALS BETWEEN 2018 AND 2021

TABLE 48 US: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)

TABLE 49 US: ENDOTHERAPY DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)

TABLE 50 US: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PROCEDURE, 2019–2026 (USD MILLION)

TABLE 51 US: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY END USER, 2019–2026 (USD MILLION)**10.2.2 CANADA**

10.2.2.1 High costs of endoscopic retrograde cholangiopancreatography to restrain the market growth in Canada

TABLE 52 INCIDENCE ESTIMATES BY CANCER TYPE (CANADA)**TABLE 53 CANADA: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)****TABLE 54 CANADA: ENDOTHERAPY DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)****TABLE 55 CANADA: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PROCEDURE, 2019–2026 (USD MILLION)****TABLE 56 CANADA: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY END USER, 2019–2026 (USD MILLION)****10.3 EUROPE****TABLE 57 EUROPE: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY COUNTRY, 2019–2026 (USD MILLION)****TABLE 58 EUROPE: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)****TABLE 59 EUROPE: ENDOTHERAPY DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)****TABLE 60 EUROPE: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PROCEDURE, 2019–2026 (USD MILLION)****TABLE 61 EUROPE: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY END USER, 2019–2026 (USD MILLION)****10.3.1 GERMANY**

10.3.1.1 Germany's rising geriatric population is one of the key drivers for the ERCP market

TABLE 62 GERMANY: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)**TABLE 63 GERMANY: ENDOTHERAPY DEVICES MARKET, BY TYPE, 2019–2026**

(USD MILLION)

TABLE 64 GERMANY: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PROCEDURE, 2019–2026 (USD MILLION)

TABLE 65 GERMANY: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY END USER, 2019–2026 (USD MILLION)

10.3.2 UK

10.3.2.1 Investments by hospitals to purchase new & advanced ERCP equipment is expected to propel market growth in the UK

TABLE 66 UK: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)

TABLE 67 UK: ENDOTHERAPY DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)

TABLE 68 UK: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PROCEDURE, 2019–2026 (USD MILLION)

TABLE 69 UK: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY END USER, 2019–2026 (USD MILLION)

10.3.3 FRANCE

10.3.3.1 High healthcare expenditure is expected to support the growth of the ERCP market in France

TABLE 70 FRANCE: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)

TABLE 71 FRANCE: ENDOTHERAPY DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)

TABLE 72 FRANCE: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PROCEDURE, 2019–2026 (USD MILLION)

TABLE 73 FRANCE: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY END USER, 2019–2026 (USD MILLION)

10.3.4 SPAIN

10.3.4.1 Increasing prevalence of cardiovascular diseases in Spain to stimulate the market growth for endoscopes

TABLE 74 SPAIN: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)

TABLE 75 SPAIN: ENDOTHERAPY DEVICES MARKET, BY TYPE, 2019–2026 (USD

MILLION)

TABLE 76 SPAIN: ENDOSCOPIC RETROGRADE

CHOLANGIOPANCREATOGRAPHY MARKET, BY PROCEDURE, 2019–2026 (USD MILLION)

TABLE 77 SPAIN: ENDOSCOPIC RETROGRADE

CHOLANGIOPANCREATOGRAPHY MARKET, BY END USER, 2019–2026 (USD MILLION)

10.3.5 ITALY

10.3.5.1 Rising government initiatives for the adoption of advanced medical equipment to drive the market growth for ERCP equipment & procedures in Italy

TABLE 78 ITALY: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)

TABLE 79 ITALY: ENDOTHERAPY DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)

TABLE 80 ITALY: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PROCEDURE, 2019–2026 (USD MILLION)

TABLE 81 ITALY: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY END USER, 2019–2026 (USD MILLION)

10.3.6 REST OF EUROPE (ROE)

TABLE 82 ROE: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)

TABLE 83 ROE: ENDOTHERAPY DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)

TABLE 84 ROE: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PROCEDURE, 2019–2026 (USD MILLION)

TABLE 85 ROE: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY END USER, 2019–2026 (USD MILLION)

10.4 ASIA PACIFIC

FIGURE 33 ASIA PACIFIC: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SNAPSHOT

TABLE 86 ASIA PACIFIC: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY COUNTRY, 2019–2026 (USD MILLION)

TABLE 87 ASIA PACIFIC: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)

TABLE 88 ASIA PACIFIC: ENDOTHERAPY DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)

TABLE 89 ASIA PACIFIC: ENDOSCOPIC RETROGRADE

CHOLANGIOPANCREATOGRAPHY MARKET, BY PROCEDURE, 2019–2026 (USD MILLION)

TABLE 90 ASIA PACIFIC: ENDOSCOPIC RETROGRADE

CHOLANGIOPANCREATOGRAPHY MARKET, BY END USER, 2019–2026 (USD MILLION)

10.4.1 JAPAN

10.4.1.1 Supportive medical device reimbursement policies to drive the market growth for ERCP in Japan

TABLE 91 JAPAN ENDOSCOPIC RETROGRADE

CHOLANGIOPANCREATOGRAPHY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)

TABLE 92 JAPAN: ENDOTHERAPY DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)

TABLE 93 JAPAN: ENDOSCOPIC RETROGRADE

CHOLANGIOPANCREATOGRAPHY MARKET, BY PROCEDURE, 2019–2026 (USD MILLION)

TABLE 94 JAPAN: ENDOSCOPIC RETROGRADE

CHOLANGIOPANCREATOGRAPHY MARKET, BY END USER, 2019–2026 (USD MILLION)

10.4.2 CHINA

10.4.2.1 Large patient population and the strong need for healthcare infrastructure improvements to drive the market growth in China

TABLE 95 CHINA: ENDOSCOPIC RETROGRADE

CHOLANGIOPANCREATOGRAPHY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)

TABLE 96 CHINA: ENDOTHERAPY DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)

TABLE 97 CHINA: ENDOSCOPIC RETROGRADE

CHOLANGIOPANCREATOGRAPHY MARKET, BY PROCEDURE, 2019–2026 (USD MILLION)

TABLE 98 CHINA: ENDOSCOPIC RETROGRADE

CHOLANGIOPANCREATOGRAPHY MARKET, BY END USER, 2019–2026 (USD MILLION)

10.4.3 INDIA

10.4.3.1 Favorable government initiatives for improvements in healthcare infrastructure to support the market growth for ERCP in India

TABLE 99 INDIA: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)

TABLE 100 INDIA: ENDOTHERAPY DEVICES MARKET, BY TYPE, 2019–2026 (USD

MILLION)

TABLE 101 INDIA: ENDOSCOPIC RETROGRADE
CHOLANGIOPANCREATOGRAPHY MARKET, BY PROCEDURE, 2019–2026 (USD
MILLION)

TABLE 102 INDIA: ENDOSCOPIC RETROGRADE
CHOLANGIOPANCREATOGRAPHY MARKET, BY END USER, 2019–2026 (USD
MILLION)

10.4.4 AUSTRALIA

10.4.4.1 The high number of cancer rates in Australia is expected to drive the demand for endoscopy instruments

TABLE 103 AUSTRALIA: ENDOSCOPIC RETROGRADE
CHOLANGIOPANCREATOGRAPHY MARKET, BY PRODUCT, 2019–2026 (USD
MILLION)

TABLE 104 AUSTRALIA: ENDOTHERAPY DEVICES MARKET, BY TYPE, 2019–2026
(USD MILLION)

TABLE 105 AUSTRALIA: ENDOSCOPIC RETROGRADE
CHOLANGIOPANCREATOGRAPHY MARKET, BY PROCEDURE, 2019–2026 (USD
MILLION)

TABLE 106 AUSTRALIA: ENDOSCOPIC RETROGRADE
CHOLANGIOPANCREATOGRAPHY MARKET, BY END USER, 2019–2026 (USD
MILLION)

10.4.5 REST OF ASIA PACIFIC (ROAPAC)

TABLE 107 ROAPAC: ENDOSCOPIC RETROGRADE
CHOLANGIOPANCREATOGRAPHY MARKET, BY PRODUCT, 2019–2026 (USD
MILLION)

TABLE 108 ROAPAC: ENDOTHERAPY DEVICES MARKET, BY TYPE, 2019–2026
(USD MILLION)

TABLE 109 ROAPAC: ENDOSCOPIC RETROGRADE
CHOLANGIOPANCREATOGRAPHY MARKET, BY PROCEDURE, 2019–2026 (USD
MILLION)

TABLE 110 ROAPAC: ENDOSCOPIC RETROGRADE
CHOLANGIOPANCREATOGRAPHY MARKET, BY END USER, 2019–2026 (USD
MILLION)

10.5 LATIN AMERICA

10.5.1 THE GOVERNMENTS IN MANY LATIN AMERICAN COUNTRIES ARE FOCUSED ON IMPROVING HEALTHCARE INFRASTRUCTURE, AND IN TURN, THE ADOPTION OF ERCP IS EXPECTED TO RISE

TABLE 111 LATIN AMERICA: ENDOSCOPIC RETROGRADE
CHOLANGIOPANCREATOGRAPHY MARKET, BY PRODUCT, 2019–2026 (USD

MILLION)

TABLE 112 LATIN AMERICA: ENDOTHERAPY DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)

TABLE 113 LATIN AMERICA: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PROCEDURE, 2019–2026 (USD MILLION)

TABLE 114 LATIN AMERICA: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY END USER, 2019–2026 (USD MILLION)

10.5.2 MIDDLE EAST

10.5.2.1 Healthcare infrastructural advancements are expected to create the requirement for advanced hospital equipment such as ERCP in the region

TABLE 115 MIDDLE EAST: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)

TABLE 116 MIDDLE EAST: ENDOTHERAPY DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)

TABLE 117 MIDDLE EAST: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PROCEDURE, 2019–2026 (USD MILLION)

TABLE 118 MIDDLE EAST: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY END USER, 2019–2026 (USD MILLION)

10.5.3 AFRICA

10.5.3.1 High prevalence of target diseases and initiatives to strengthen endoscopic services in healthcare organizations to propel market growth

TABLE 119 AFRICA: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)

TABLE 120 AFRICA: ENDOTHERAPY DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)

TABLE 121 AFRICA: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PROCEDURE, 2019–2026 (USD MILLION)

TABLE 122 AFRICA: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY END USER, 2019–2026 (USD MILLION)

11 COMPETITIVE LANDSCAPE

11.1 OVERVIEW

11.2 KEY PLAYER STRATEGIES/RIGHT-TO-WIN

11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN THE
ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET

11.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS

FIGURE 34 REVENUE ANALYSIS OF KEY PLAYERS IN ENDOSCOPIC
RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET

11.4 COMPETITIVE BENCHMARKING

TABLE 123 FOOTPRINT OF COMPANIES IN ENDOSCOPIC RETROGRADE
CHOLANGIOPANCREATOGRAPHY MARKET

TABLE 124 PRODUCT AND SERVICE: COMPANY FOOTPRINT (25 COMPANIES)

TABLE 125 END USER: COMPANY FOOTPRINT (25 COMPANIES)

TABLE 126 REGION: COMPANY FOOTPRINT (26 COMPANIES)

11.5 COMPETITIVE LEADERSHIP MAPPING

11.5.1 STAR

11.5.2 EMERGING LEADER

11.5.3 PERVASIVE PLAYER

11.5.4 PARTICIPANT

FIGURE 35 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY
MARKET: COMPETITIVE LEADERSHIP MAPPING (2020)

11.6 COMPETITIVE LEADERSHIP MAPPING FOR OTHER COMPANIES

11.6.1 PROGRESSIVE COMPANY

11.6.2 DYNAMIC COMPANY

11.6.3 STARTING BLOCK

11.6.4 RESPONSIVE COMPANY

FIGURE 36 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY
MARKET: COMPETITIVE LEADERSHIP MAPPING FOR OTHER COMPANIES (2020)

11.7 MARKET RANKING ANALYSIS

FIGURE 37 ERCP MARKET RANKING ANALYSIS, BY PLAYER, 2020

FIGURE 38 ENDOTHERAPY DEVICES MARKET RANKING ANALYSIS, BY PLAYER,
2020

11.8 COMPETITIVE SCENARIO

TABLE 127 PRODUCT LAUNCHES & APPROVALS, 2019–2021

TABLE 128 DEALS, 2019–2021

12 COMPANY PROFILES

(Business overview, Products offered, Recent developments, MnM view, Right to win,

Weakness and competitive threats, and Strategic choices made)*

12.1 KEY PLAYERS

12.1.1 OLYMPUS CORPORATION

TABLE 129 OLYMPUS CORPORATION: BUSINESS OVERVIEW

FIGURE 39 COMPANY SNAPSHOT: OLYMPUS CORPORATION (2020)

12.1.2 CONMED CORPORATION

TABLE 130 CONMED CORPORATION: BUSINESS OVERVIEW

FIGURE 40 COMPANY SNAPSHOT: CONMED CORPORATION (2020)

12.1.3 AMBU A/S

TABLE 131 AMBU A/S: BUSINESS OVERVIEW

FIGURE 41 COMPANY SNAPSHOT: AMBU A/S (2020)

12.1.4 BOSTON SCIENTIFIC CORPORATION

TABLE 132 BOSTON SCIENTIFIC CORPORATION: BUSINESS OVERVIEW

FIGURE 42 COMPANY SNAPSHOT: BOSTON SCIENTIFIC CORPORATION (2020)

12.1.5 JOHNSON & JOHNSON

TABLE 133 JOHNSON & JOHNSON: BUSINESS OVERVIEW

FIGURE 43 COMPANY SNAPSHOT: JOHNSON & JOHNSON (2020)

12.1.6 FUJIFILM HOLDINGS CORPORATION

TABLE 134 FUJIFILM HOLDINGS CORPORATION: BUSINESS OVERVIEW

FIGURE 44 COMPANY SNAPSHOT: FUJIFILM HOLDINGS CORPORATION (2020)

12.1.7 MEDTRONIC, PLC

TABLE 135 MEDTRONIC, PLC: BUSINESS OVERVIEW

FIGURE 45 COMPANY SNAPSHOT: MEDTRONIC, PLC (2020)

12.1.8 KARL STORZ SE & CO. KG

TABLE 136 KARL STORZ SE & CO. KG.: BUSINESS OVERVIEW

12.1.9 COOK MEDICAL

TABLE 137 COOK MEDICAL: BUSINESS OVERVIEW

12.1.10 HOYA CORPORATION

TABLE 138 HOYA CORPORATION: BUSINESS OVERVIEW

FIGURE 46 COMPANY SNAPSHOT: HOYA CORPORATION (2020)

12.1.11 B. BRAUN MELSUNGEN AG

TABLE 139 B. BRAUN MELSUNGEN AG: BUSINESS OVERVIEW

FIGURE 47 COMPANY SNAPSHOT: B. BRAUN MELSUNGEN AG (2020)

12.1.12 HOBBS MEDICAL, INC.

TABLE 140 HOBBS MEDICAL, INC.: BUSINESS OVERVIEW

12.1.13 STERIS PLC

FIGURE 48 COMPANY SNAPSHOT: STERIS PLC (2020)

TABLE 141 STERIS PLC: BUSINESS OVERVIEW

12.1.14 MERIT MEDICAL SYSTEMS, INC.

TABLE 142 MERIT MEDICAL SYSTEMS, INC.: BUSINESS OVERVIEW
FIGURE 49 COMPANY SNAPSHOT: MERIT MEDICAL SYSTEMS, INC. (2020)
12.1.15 TELEMED SYSTEMS, INC.
TABLE 143 TELEMED SYSTEMS, INC.: BUSINESS OVERVIEW
12.1.16 CHANGZHOU HEALTH MICROPORT MEDICAL DEVICE CO., LTD.
TABLE 144 CHANGZHOU HEALTH MICROPORT MEDICAL DEVICE CO., LTD.:
BUSINESS OVERVIEW
12.1.17 MEDI-GLOBE GMBH
TABLE 145 MEDI-GLOBE GMBH: BUSINESS OVERVIEW
12.1.18 TAEWOONG MEDICAL CO., LTD.
TABLE 146 TAEWOONG MEDICAL CO., LTD.: BUSINESS OVERVIEW
12.1.19 HUGER MEDICAL INSTRUMENT CO., LTD.
TABLE 147 HUGER MEDICAL INSTRUMENT CO., LTD.: BUSINESS OVERVIEW
12.1.20 INTROMEDIC CO., LTD.
TABLE 148 INTROMEDIC CO., LTD.: BUSINESS OVERVIEW
FIGURE 50 COMPANY SNAPSHOT: INTROMEDIC CO., LTD. (2020)
12.1.21 SONOSCAPE MEDICAL CORP.
TABLE 149 SONOSCAPE MEDICAL CORP.: BUSINESS OVERVIEW
FIGURE 51 COMPANY SNAPSHOT: SONOSCAPE MEDICAL CORP (2020)
12.2 OTHER PLAYERS
*Details on Business overview, Products offered, Recent developments, MnM view, Right to win, Weakness and competitive threats, and Strategic choices made might not be captured in case of unlisted companies.

13 APPENDIX

13.1 DISCUSSION GUIDE
13.2 KNOWLEDGE STORE: MARKETSandMARKETS' SUBSCRIPTION PORTAL
13.3 AVAILABLE CUSTOMIZATIONS
13.4 RELATED REPORTS
13.5 AUTHOR DETAILS

I would like to order

Product name: Endoscopic Retrograde Cholangiopancreatography/ERCP Market by Product (Upper GI endoscopes, Stent, Balloons, Catheters, Baskets), Procedure (Biliary Sphincterotomy & Stenting, Pancreatic Sphincterotomy), End User (Hospitals) - Global Forecast to 2026

Product link: <https://marketpublishers.com/r/ECA7122C8DF9EN.html>

Price: US\$ 4,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/ECA7122C8DF9EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970